Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

62.71USD
27 May 2016
Change (% chg)

$0.81 (+1.31%)
Prev Close
$61.90
Open
$61.99
Day's High
$63.19
Day's Low
$61.90
Volume
1,636,165
Avg. Vol
2,201,765
52-wk High
$71.59
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $101,424.60
Shares Outstanding(Mil.): 1,617.36
Dividend: 0.57
Yield (%): 3.64

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.79 35.22 36.14
EPS (TTM): 3.34 -- --
ROI: 18.66 13.74 13.10
ROE: 181.93 14.88 14.37

Biogen, AbbVie once-monthly MS injection wins U.S. approval

The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

28 May 2016

UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval

May 27 The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

28 May 2016

BRIEF-AbbVie's Humira receives CHMP positive opinion to treat non-infectious uveitis

* AbbVie's Humira receives CHMP positive opinion to treat certain forms of non-infectious uveitis, a disease that can severely impact vision

27 May 2016

BRIEF-Abbvie IL-23 Inhibitor Risankizumab induces remission in Phase II Study

* IL-23 inhibitor risankizumab induces remission in phase ii study in patients with moderate-to-severe crohn's disease

24 May 2016

Coherus says U.S. Patent Office to review AbbVie's Humira

Coherus BioSciences Inc said on Tuesday the U.S. Patent and Trademark Office had agreed to review its petition to make a copy of AbbVie Inc's top-selling arthritis drug Humira.

17 May 2016

BRIEF-AbbVie says Humira protected by many patents covering all aspects of manufacture, formulation and indications

* "we are confident in the validity of our patents and will vigorously defend them"

17 May 2016

Coherus says U.S. Patent Office to review AbbVie's Humira

May 17 Coherus BioSciences Inc said on Tuesday the U.S. Patent and Trademark office had agreed to review its petition to make a copy of AbbVie Inc's top-selling artritis drug Humira.

17 May 2016

BRIEF-Paulson & Co dissolves in Abbvie, takes in Expedia

* Paulson & Co Inc Dissolves Share Stake In Abbvie Inc - Sec filing

17 May 2016

Ablynx burns more cash in first-quarter on higher R&D costs

Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.

12 May 2016

AbbVie forges deeper into cancer, as clock ticks for Humira

AbbVie Inc placed another big bet on new cancer drugs on Thursday with a $5.8 billion acquisition that could lessen its dependence on arthritis treatment Humira, the world's top selling drug.

29 Apr 2016

Competitors

Earnings vs. Estimates